NEXTRACKER
14.3.2023 07:04:42 CET | Business Wire | Press release
Nextracker Inc. (NASDAQ: NXT) secured a new deal in Europe for its terrain-following solar tracker NX Horizon-XTR™ (XTR), demonstrating demand for tracking technology that enables solar developers to build on land with complex topography and unique environmental constraints. The German international solar developer, IbVogt, chose Nextracker’s XTR for the 150 MW Garnacha solar power plant in Spain. The project is backed by a 12-year power purchase agreement (PPA) with Google and is expected to begin production October of 2023. Leading the global market in solar trackers and optimization software, Nextracker’s advanced technology systems allow solar panels to follow the sun’s movement and maximize energy output.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230313005879/en/
European Renewable Energy Developer IbVogt chooses Nextracker’s NX Horizon-XTR for its upcoming 150 MW project in Spain (Photo: Business Wire)
“Due to the local zero grading requirements on our project, we needed a solar tracker solution that would have minimal environmental impact and allow us to secure local permits,“ stated Patrick Zenker, Global Procurement Director of IbVogt. ” With a 10-gigawatt track record, NX Horizon-XTR gave us peace of mind and low risk."
“With gas price volatility, European leaders are looking for the lowest cost, most reliable form of energy, and that is utility scale solar power,” said Dan Shugar, Founder and CEO of Nextracker. “Europe’s exceptional environmental stewardship, unique cultural sites and challenging topography provide the perfect conditions for our terrain-following trackers that maximize energy output with a light-on-land footprint.”
Nextracker’s NX Horizon-XTR™ allows rows of solar panels to adjust to uneven terrain, following the natural curvature of the earth. Its terrain-following capabilities enable developers to work on challenging sites that would otherwise be infeasible. It also cuts costs by limiting grading work and associated delays, simplifying the permitting process, and reducing the need for soil-related maintenance.
Solar projects using NX Horizon-XTR have a lighter impact on the environment as they leave more soil intact, benefitting the local ecology and reducing risk of soil erosion. The projects also require less steel for extended pilings, lowering a project’s overall carbon footprint.
The Garnacha project expands Nextracker’s multi-gigawatt portfolio in Europe. The company has offices in Seville and Madrid, with dedicated employees working with customers across the continent with deep expertise to support the life cycle of every project.
“The Nextracker European team has achieved an important milestone of reaching over 3 GW of projects with major solar developers, utilities and European EPC companies for projects in Europe as well as Brazil, USA, Canada and Africa,” said Arturo Herrero, Nextracker SVP Europe.
Nextracker, a leading solar tracking company with 70 GW shipped globally to five continents, has deployed their terrain-following NX-Horizon XTR on close to 10 GW of utility-scale solar globally. Nextracker’s solar trackers increase energy production by 20-30% more than fixed-tilt applications that do not track the sun.
About Nextracker
Nextracker is a leading provider of intelligent, integrated solar tracker and software solutions used in utility-scale and ground-mounted distributed generation solar projects around the world. Our products enable solar panels in utility-scale power plants to follow the sun’s movement across the sky and optimize plant performance. With more than 70 gigawatts shipped worldwide, Nextracker offers solar tracker technologies that optimize and increase energy production while reducing costs for significant plant ROI. For more information, please visit Nextracker.
Stay in touch with us: Twitter LinkedIn Instagram Facebook
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230313005879/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom